AbCellera Biologics (ABCL) Invested Capital (2020 - 2025)

AbCellera Biologics (ABCL) has 6 years of Invested Capital data on file, last reported at $8.8 million in Q1 2025.

• Quarterly Invested Capital fell 82.95% year-over-year to $8.8 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $8.8 million (down 91.21% YoY) and the FY2024 annual result came in at $8.1 million, down 83.98% from the prior year.
• Invested Capital climbed to $8.8 million in Q1 2025, from $8.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $54.9 million in Q2 2023 to a low of $8.1 million in Q4 2024.
• A 5-year average of $30.0 million and a median of $27.5 million in 2022 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital soared 195.99% — and 2024, when it slumped 83.98%.
• Tracing ABCL's Invested Capital over 5 years: stood at $22.9 million in 2021, then jumped by 92.77% to $44.2 million in 2022, then advanced by 14.17% to $50.5 million in 2023, then tumbled by 83.98% to $8.1 million in 2024, then climbed by 8.46% to $8.8 million in 2025.
• The last three Invested Capital figures came in at $8.8 million (Q1 2025), $8.1 million (Q4 2024), and $20.2 million (Q3 2024), per Business Quant data.